Australia markets closed

Taro Pharmaceutical Industries Ltd. (TARO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
42.19-0.05 (-0.12%)
At close: 04:00PM EDT
42.19 -0.03 (-0.06%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.59B
Enterprise value 737.36M
Trailing P/E 34.58
Forward P/E 9.81
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.60
Price/book (mrq)0.89
Enterprise value/revenue 1.21
Enterprise value/EBITDA 9.53

Trading information

Stock price history

Beta (5Y monthly) 0.61
52-week change 371.43%
S&P500 52-week change 321.23%
52-week high 345.76
52-week low 324.39
50-day moving average 342.13
200-day moving average 339.05

Share statistics

Avg vol (3-month) 349.36k
Avg vol (10-day) 323.95k
Shares outstanding 537.58M
Implied shares outstanding 637.67M
Float 88.09M
% held by insiders 178.48%
% held by institutions 113.43%
Shares short (28 Mar 2024) 439.81k
Short ratio (28 Mar 2024) 40.88
Short % of float (28 Mar 2024) 40.49%
Short % of shares outstanding (28 Mar 2024) 40.11%
Shares short (prior month 29 Feb 2024) 458.78k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 328 Dec 2018
Ex-dividend date 410 Dec 2018
Last split factor 22:1
Last split date 327 July 2001

Financial highlights

Fiscal year

Fiscal year ends 31 Mar 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 7.48%
Operating margin (ttm)10.69%

Management effectiveness

Return on assets (ttm)1.03%
Return on equity (ttm)2.61%

Income statement

Revenue (ttm)610.83M
Revenue per share (ttm)16.25
Quarterly revenue growth (yoy)12.90%
Gross profit (ttm)N/A
EBITDA 68.88M
Net income avi to common (ttm)45.7M
Diluted EPS (ttm)1.22
Quarterly earnings growth (yoy)178.20%

Balance sheet

Total cash (mrq)902.22M
Total cash per share (mrq)24
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.60
Book value per share (mrq)47.33

Cash flow statement

Operating cash flow (ttm)142.87M
Levered free cash flow (ttm)81.01M